TACSTD2
ENSG00000184292
Target class
Unclassified protein
Chromosome
1
Approved drugs
1
Clinical candidates (approved and in development)
2
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- No
- Target name
- TACSTD2
- Gene name
- Tumor associated calcium signal transducer 2
- Gene symbol
- TACSTD2
- Previous gene symbols
- M1S1
- Protein name
- Tumor-associated calcium signal transducer 2 (Cell surface glycoprotein Trop-2) (Membrane component chromosome 1 surface marker 1) (Pancreatic carcinoma marker protein GA733-1)
- TROP2
- GA733-1
- EGP-1
- Gene biotype
- Protein coding
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 36
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 1,419.1
- Tissue specificity (Gini)
- 0.876
- Tissue specificity (tau)
- 0.952
- KEGG gene identifiers
- hsa:4070
- Protein interaction confidence
- 0.809833
- Protein interaction partners
- 6
- End position
- 58577252
- Start position
- 58575433
- Chromosome
- 1
- Strand
- Reverse
- Membrane
- Single-pass type I membrane protein.
- Nucleoli
- Plasma membrane
- Vesicles
- Tissue specificity (tau)
- 0.952015
- Expression inequality (Gini)
- 0.876374
Expression in transcripts per million
- Esophagus - Mucosa
- 1,419.1
- Skin - Not Sun Exposed (Suprapubic)
- 708.7
- Skin - Sun Exposed (Lower leg)
- 683.92
- Minor Salivary Gland
- 680.75
- Vagina
- 655.98
Expression in transcripts per million
- Esophagus - Mucosa1,419.1
- Skin - Not Sun Exposed (Suprapubic)708.7
- Skin - Sun Exposed (Lower leg)683.92
- Minor Salivary Gland680.75
- Vagina655.98
- Kidney - Medulla218.48
- Prostate154.07
- Breast - Mammary Tissue131.47
- Lung118.69
- Kidney - Cortex59.22
- Pancreas46.47
- Bladder38.39
- Fallopian Tube18.22
- Nerve - Tibial11.65
- Stomach9.72
- Thyroid8.1
- Adipose - Subcutaneous6.28
- Artery - Aorta6.04
- Artery - Tibial5.06
- Cervix - Ectocervix5.05
- Uterus4.84
- Cervix - Endocervix4.15
- Artery - Coronary3.98
- Cells - Cultured fibroblasts2.93
- Adipose - Visceral (Omentum)2.23
And 29 more, listed on the interactive page.
Biological processes
- GO:0007601
- GO:0005829
- GO:0005886
- GO:0016020
- GO:0070062
Molecular functions
- GO:0005515
Related records
Trials (185)
- A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer
- A Multicenter, Prospective, Phase II Study of TROP-2 ADC in Combination With Toripalimab for Resectable Locally Advanced Oral Squamous Cell Carcinoma
- A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
- A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)
- A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
- A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
- A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
- A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
- A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
- A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)
- A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
- A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
- A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)
- A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
- A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
- A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Drugs (2)
- Datopotamab deruxtecan Tumor-associated calcium signal transducer 2 binding agent
- Sacituzumab govitecan Tumor-associated calcium signal transducer 2 binding agent